Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.
FDA expert group 7:2 supports the retention of Tecentriq triple-negative breast cancer...
Kangfang Bio-PD-1/CTLA-4 Dual Antibody Approved Global Phase 3 Clinical First-line Treatment for Advanced Cervical Cancer
Molecular Cancer | 2 articles in a row!
Hengrui Medicine's application for the listing of CDK 4/6 inhibitors has been accepted and R&D investment nearly 2...
How to avoid severe hypoglycemia in elderly patients with type 2 diabetes who started insulin
The cause of the cough cannot be found for 2 years, the "murderer" turned out to be it!
Follow up with the new concept of type 2 diabetes prevention and treatment in China, and interpret the updated points of the new CDS 2020 guide
Prof. Xu Wei: Current status and resistance mechanism of BCL-2 inhibitors in CLL
Interpretation of Chinese Guidelines for Diabetic Nephropathy (Part 2)
NEJM publishes Phase 3 results of Johnson & Johnson's single-dose new crown vaccine: prevent 2/3 of moderate to severe diseases, effective in South Africa
Results of two Phase III studies of Bristol-Myers Squibb's oral TYK-2 inhibitor announced (with PPT)
Express | Aims to "functionally cure" hepatitis B, phase 2 clinical trial of innovative combination therapy starts
; PD-1/CTLA-4 dual antibody was approved to carry out a phase III clinical trial for the first-line treatment of advanced cervical cancer|Tumor News
Announcement of Nantong City Food Safety Supervision Sampling Inspection Results in 2021 (Phase 2)
Kangfang Bio-PD-1/CTLA-4 was approved to start a global phase 3 clinical trial for the treatment of cervical cancer
Drug release: The FDA expert team supports the retention of T drugs for the first-line treatment of mTNBC with 7:2
Announcement of Maoming City Market Supervision Administration on 7 batches of unqualified foods (Phase 2 of 2021)
LANCET: The complete elimination of SARS-CoV-2 can create the best results for health, economy and civil liberties
FDA expert group 7:2 supports the retention of Tecentriq triple-negative breast cancer indication